f COVID-19―Where Are We Now

References

1. Looi M.K. Will we ever know where covid-19 came from? BMJ 2024 386 q1578 10.1136/bmj.q1578 39251233
   [Google Scholar]
2. Chen J. Does COVID-19 decrease price dispersion? Recent evidence from the airline industry. Res. Econ. 2024 78 2 100955 10.1016/j.rie.2024.100955
   [Google Scholar]
3. Cano-Guervos R. Chica-Olmo J. Chica-Garcia J. The effect of disruptive change on the spatial variation of commercial rental prices: The case of the COVID-19 pandemic. J. Retailing Consum. Serv. 2025 82 104111 [PMID]. 10.1016/j.jretconser.2024.104111
   [Google Scholar]
4. Palandri L. Rizzi C. Vandelli V. Filippini T. Ghinoi A. Carrozzi G. Girolamo G.D. Morlini I. Coratza P. Giovannetti E. Russo M. Soldati M. Righi E. Azzalini D. Barbieri R. Bechtold P. Borsari L. Creola G. Ferrari A. Ferrari D. Ferrari E. Fioretti E. Gatti M.G. Iacuzio L. Iseppi R. Lugli C. Monti M. Morciano M. DISCOV-19 study group Environmental, climatic, socio-economic factors and non-pharmacological interventions: A comprehensive four-domain risk assessment of COVID-19 hospitalization and death in Northern Italy. Int. J. Hyg. Environ. Health 2025 263 114471 10.1016/j.ijheh.2024.114471 39366078
   [Google Scholar]
5. Conte C. Cipponeri E. Roden M. Diabetes mellitus, energy metabolism, and covid-19. Endocr. Rev. 2024 45 2 281 308 10.1210/endrev/bnad032 37934800
   [Google Scholar]
6. Iacopetta D. Catalano A. Ceramella J. Pellegrino M. Marra M. Scali E. Sinicropi M. Aquaro S. The ongoing impact of covid-19 on pediatric obesity. Pediatr. Rep. 2024 16 1 135 150 10.3390/pediatric16010013 38391001
   [Google Scholar]
7. Lyzwinski L. Zwicker J.D. Mcdonald S. Tough S. Psychological interventions and those with elements of positive psychology for child and youth mental health during the covid-19 pandemic: Literature review, lessons learned, and areas for future knowledge dissemination. JMIR Pediatr. Parent. 2024 7 e59171 10.2196/59171 39269752
   [Google Scholar]
8. Fedeli U. Barbiellini Amidei C. Han X. Jemal A. Changes in cancer-related mortality during the COVID-19 pandemic in the United States. J. Natl. Cancer Inst. 2024 116 1 167 169 10.1093/jnci/djad191 37688577
   [Google Scholar]
9. Catalano A. Iacopetta D. Ceramella J. Pellegrino M. Giuzio F. Marra M. Rosano C. Saturnino C. Sinicropi M.S. Aquaro S. Antibiotic-resistant ESKAPE pathogens and covid-19: The pandemic beyond the pandemic. Viruses 2023 15 9 1843 10.3390/v15091843 37766250
   [Google Scholar]
10. Krishna B.A. Metaxaki M. Sithole N. Landín P. Martín P. Salinas-Botrán A. Cardiovascular disease and covid-19: A systematic review. Int. J. Cardiol. Heart Vasc. 2024 54 101482 10.1016/j.ijcha.2024.101482 39189008
    [Google Scholar]
11. Rico-Mesa J.S. Haloot J. Anupama B.K. Atluri S. Liu J. Khalid U. The role and implications of covid-19 in incident and prevalent heart failure. Curr. Heart Fail. Rep. 2024 21 5 485 497 10.1007/s11897‑024‑00677‑7 39042238
    [Google Scholar]
12. Ceramella J. Iacopetta D. Sinicropi M.S. Andreu I. Mariconda A. Saturnino C. Giuzio F. Longo P. Aquaro S. Catalano A. Drugs for covid-19: An update. Molecules 2022 27 23 8562 10.3390/molecules27238562 36500655
    [Google Scholar]
13. Iacopetta D. Ceramella J. Catalano A. Saturnino C. Pellegrino M. Mariconda A. Longo P. Sinicropi M.S. Aquaro S. COVID-19 at a glance: An up-to-date overview on variants, drug design and therapies. Viruses 2022 14 3 573 10.3390/v14030573 35336980
    [Google Scholar]
14. Kabi A.K. Pal M. Gujjarappa R. Malakar C.C. Roy M. Overview of hydroxychloroquine and remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). J. Heterocycl. Chem. 2023 60 2 165 182 10.1002/jhet.4541 35942205
    [Google Scholar]
15. Catalano A. Iacopetta D. Ceramella J. Maio A.C.D. Basile G. Giuzio F. Bonomo M.G. Aquaro S. Walsh T.J. Sinicropi M.S. Saturnino C. Geronikaki A. Salzano G. Are nutraceuticals effective in covid-19 and post-covid prevention and treatment? Foods 2022 11 18 2884 10.3390/foods11182884 36141012
    [Google Scholar]
16. Gasmi A. Noor S. Menzel A. Khanyk N. Semenova Y. Lysiuk R. Beley N. Bolibrukh L. Gasmi Benahmed A. Storchylo O. Bjørklund G. Potential drugs in covid-19 management. Curr. Med. Chem. 2024 31 22 3245 3264 10.2174/0929867331666230717154101 37461346
    [Google Scholar]
17. Mitev V. Colchicine—the divine medicine against covid-19. J. Pers. Med. 2024 14 7 756 10.3390/jpm14070756 39064010
    [Google Scholar]
18. Shafiee A. Jafarabady K. Moltazemi H. Amini M.J. Rafiei M.A. Akhondi A. Mozhgani S.H. Alkalinization using sodium bicarbonate for covid-19 treatment: A systematic review and meta-analysis. J. Evid. Based Integr. Med. 2024 29 2515690X241258403 10.1177/2515690X241258403 38826036
    [Google Scholar]
19. Mitev V. Mondeshki T. Miteva A. Tashkov K. Dimitrova V. Covid-19 prophylactic effect of bromhexine hydrochloride. Preprints 2024 2024101998 10.20944/preprints202410.1998.v1
    [Google Scholar]
20. Woods J.A. Hutchinson N.T. Powers S.K. Roberts W.O. Gomez-Cabrera M.C. Radak Z. Berkes I. Boros A. Boldogh I. Leeuwenburgh C. Coelho-Júnior H.J. Marzetti E. Cheng Y. Liu J. Durstine J.L. Sun J. Ji L.L. The COVID-19 pandemic and physical activity. Sports Med. Health Sci. 2020 2 2 55 64 10.1016/j.smhs.2020.05.006 34189484
    [Google Scholar]
21. Catalano A. COVID-19: Could Irisin become the handyman myokine of the 21st century? Coronaviruses 2020 1 1 32 41 [PMID]. 10.2174/2666796701999200617154655
    [Google Scholar]
22. WHO WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/
23. Hofmeyer K.A. Ventura C.L. Armstrong K.L. Houchens C.R. Patel S. Disbrow G.L. Johnson R.A. Bandremer A.C. Beigel J.H. Belski T.T. Donis R.O. Jayashankar L. Koup R.A. Kovacs G.R. Link M.A. Martins K.A. Mason R.M. Stronsky S.M. Wolfe D.N. Project NextGen Line of Effort Leads Project nextgen: Developing the next generation of covid-19 vaccines and therapeutics to respond to the present and prepare for the future. Clin. Infect. Dis. 2024 79 1 115 121 10.1093/cid/ciae073 38356144
    [Google Scholar]
24. Hernandez A.V. Liu A. Roman Y.M. Burela P.A. Pasupuleti V. Thota P. Carranza-Tamayo C.O. Retamozo-Palacios M. Benites-Zapata V.A. Piscoya A. Vidal J.E. Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants. Int. J. Antimicrob. Agents 2024 64 2 107248 10.1016/j.ijantimicag.2024.107248 38908535
    [Google Scholar]
25. Zhou Q. Zhao G. Pan Y. Zhang Y. Ni Y. The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials. PLoS One 2024 19 5 e0300512 10.1371/journal.pone.0300512 38753761
    [Google Scholar]
26. Sil D. Gautam S. Saxena S. Joshi S. Kumar D. Mehta A. Jindal P. Sharma S. Pandey P. Diksha Singh A. Comprehensive analysis of omicron subvariants: EG.5 rise, vaccination strategies, and global impact. Curr. Drug Targets 2024 25 8 517 525 10.2174/0113894501296586240430061915 38726782
    [Google Scholar]
27. Parums D.V. Editorial: A rapid global increase in covid-19 is due to the emergence of the EG.5 (Eris) subvariant of omicron SARS-CoV-2. Med. Sci. Monit. 2023 29 e942244 10.12659/MSM.942244 37654205
    [Google Scholar]
28. Popović M.E. Šekularac G. Popović M. The wind of change: Gibbs energy of binding and infectivity evolution of Omicron BA.2.86 Pirola, EG.5.1, XBB.1.16 Arcturus, CH.1.1 and BN.1 variants of SARS-CoV-2. Microb. Risk Anal. 2024 26 100290 [PMID]. 10.1016/j.mran.2024.100290
    [Google Scholar]
29. ECDC SARS-CoV-2 variants of concern as of 06 October 2023. 2023 Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern
30. WHO Tracking SARS-CoV-2 variants. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants
31. Shrestha N.K. Burke P.C. Nowacki A.S. Gordon S.M. Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine against the JN. 1 Variant. medRxiv 2024 38465901 10.1101/2024.04.27.24306378
    [Google Scholar]
32. Happle C. Hoffmann M. Kempf A. Nehlmeier I. Stankov M.V. Calderon Hampel N. Witte T. Pöhlmann S. Behrens G.M.N. Dopfer-Jablonka A. Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination. Lancet Infect. Dis. 2024 24 11 e674 e676 10.1016/S1473‑3099(24)00603‑0 39341219
    [Google Scholar]
33. EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025. Available from: https://www.google.com/search?client=firefox-b-d&q=EMA+confirms+its+recommendation+to+update+the+antigenic+composition+of+authorised+COVID-19+vaccines+for+2024-2025 (Accessed on November 5, 2024).
34. Statement on the antigen composition of COVID-19 vaccines. Available from: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines (Accessed on November 5, 2024).
35. World Health Organization (WHO) COVID-19 vaccines with WHO emergency use listing. Available from: https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing (Accessed on November 5, 2024).
36. European Medicines Agency (EMA) COVID-19 Medicines. Authorized COVID-19 Vaccines. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines (Accessed on November 5, 2024).
37. Food and Drug Administration (FDA) COVID-19 vaccines for 2024–2025. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2024-2025 (Accessed on November 5, 2024).
38. Plans-Rubió P. What covid-19 vaccination strategy should be implemented and which vaccines should be used in the post-pandemic era? Vaccines 2024 12 10 1180 10.3390/vaccines12101180 39460346
    [Google Scholar]